Hepatitis

Health Canada has expanded its approval of Abbvie’s oral therapy Maviret (glecaprevir/pibrentasvir), making it the first eight-week, pan-genotypic treatment available for both acute and…

Throughout 2025, the team at Liver Disease News has reported on the latest research and advances in care related to various rare and non-rare liver…

Researchers in the U.S. have developed a rapid point-of-care test that detects active hepatitis C infection by identifying HCV RNA, with results available in…

Major medical associations and state health departments are moving to maintain the standard of universal hepatitis B vaccination at birth, diverging from a recent…

People with hepatitis C who show higher values of liver scarring markers before starting antiviral therapy are significantly more likely to later develop…

New modeling data predict that bemnifosbuvir and ruzasvir, an experimental combination treatment being developed by Atea Pharmaceuticals for chronic hepatitis C, may…

PBGENE-HBV, Precision BioSciences’ experimental gene-editing therapy for chronic hepatitis B, showed antiviral activity across three doses, with the highest dose approaching the benchmark…

Enrollment is now complete for Vir Biotechnology’s global ECLIPSE 1 trial, which is testing the combination treatment of tobevibart and elebsiran in people with chronic…

The European Medicines Agency (EMA) has granted orphan drug designation to Suzhou Ribo Life Science’s experimental therapy RBD1016 for hepatitis D. The EMA gives…

Kezar Life Sciences has hit a roadblock in plans to develop zetomipzomib, its experimental treatment for autoimmune hepatitis (AIH). The company has…